PROM1 and cancer: All patients without relapse showed decreasing PD-L1+ CD49f+ CD133+ CTC numbers during therapy (Fig. 4H, right, grey lines) while 28/31 patients (90%) with recurrent cancers exhibited increased post-therapeutic numbers/ml of this CTC subtype (purple lines) compared to baseline.